Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COMBINED THERAPY WITH BENAZEPRIL AND AMLODIPINE IN THE TREATMENT OF HYPERTENSION INADEQUATELY CONTROLLED BY AN ACE-INHIBITOR ALONE
Autore:
FOGARI R; COREA L; CARDONI O; COSMI F; PORCELLATI C; INNOCENTI P; PROVVIDENZA M; TIMIO M; BENTIVOGLIO M; BERTOCCHI F; ZOPPI A;
Indirizzi:
POLO UNIV CITTA PAVIA,VIA PARCO VECCHIO 27 I-27100 PAVIA ITALY UNIV PAVIA,DEPT INTERNAL MED & THERAPEUT I-27100 PAVIA ITALY UNIV PERUGIA I-06100 PERUGIA ITALY GEN HOSP GUBBIO,CARDIOL UNIT GUBBIO ITALY GEN HOSP CORTONA,DEPT INTERNAL MED CORTONA ITALY SILVESTRINI HOSP PERUGIA,DEPT CARDIOL & MED PERUGIA ITALY GEN HOSP CARRARA,DEPT INTERNAL MED CARRARA ITALY GEN HOSP GUALDO TADINO,CARDIOVASC UNIT GUALDO TADINO ITALY GEN HOSP FOLIGNO,DEPT NEPHROL FOLIGNO ITALY CIBA GEIGY CORP,DEPT MED ORIGGIO VA ITALY
Titolo Testata:
Journal of cardiovascular pharmacology
fascicolo: 4, volume: 30, anno: 1997,
pagine: 497 - 503
SICI:
0160-2446(1997)30:4<497:CTWBAA>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHARMACOKINETIC PROPERTIES; DRUG THERAPY; COMBINATION; CAPTOPRIL; NIFEDIPINE; MODERATE; EFFICACY;
Keywords:
BENAZEPRIL; AMLODIPINE; HYPERTENSION; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
R. Fogari et al., "COMBINED THERAPY WITH BENAZEPRIL AND AMLODIPINE IN THE TREATMENT OF HYPERTENSION INADEQUATELY CONTROLLED BY AN ACE-INHIBITOR ALONE", Journal of cardiovascular pharmacology, 30(4), 1997, pp. 497-503

Abstract

In a multicenter, randomized, double-blind, placebo-controlled study,we evaluated the efficacy and tolerability of the combination of benazepril, 10 mg, and amlodipine, 2.5 or 5 mg once daily, compared with benazepril, 10 mg, monotherapy in patients with hypertension inadequately controlled with angiotensin-converting enzyme (ACE)-inhibitor monotherapy. After a 2-week placebo and 4-week single-blind benazepril, 10 mg once daily, run-in period, 448 patients, 213 men and 235 women, aged 24-73 years (mean, 55 years), with mean diastolic blood pressure (DBP) greater than or equal to 95 and less than or equal to 120 mm Hg at the end of the benazepril run-in period, were randomized to receive one of the following treatments once daily for 8 weeks: (a) benazepril, 10 mg, plus placebo (BZ10); (b) benazepril, 10 mg, plus amlodipine, 2.5 mg (BZ10/AML2.5); or (c) benazepril, 10 mg, plus amlodipine, 5 mg (BZ10/AML5). Before the patients were admitted to the trial, at the end of the placebo run-in and the benazepril run-in period and at the end of weeks 4 and 8 of the treatment period, sitting and standing blood pressure (BP), heart rate (HR), and body weight were measured 22-26 h after the intake of the trial medication. Both BZ10/AML2.5 and BZ10/AML5 combinations showed better antihypertensive activity than did BZ10 monotherapy at the terminal visit as demonstrated by (a) the 24-h postdosing sitting and standing systolic BP (SEP) and DBP values, which were statistically lower with combination therapy than with BZ10; (b) thesuccess rate, which was statistically higher with both the combinations (69.2% in the BZ10/AML2.5 and 65.8% in the BZ10/AML5 group) compared with the BZ10 group (40.5%). The tolerability was good in the three treatment groups. No significant abnormal laboratory data were detected. There was no difference in efficacy and safety/tolerability betweenthe BZ10/AML2.5 and BZ10/AML5 groups.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/09/20 alle ore 10:00:27